On May 22, Zaiding Pharmaceutical announced that the first patient had been administered in a global phase 2 clinical study (NCT06380907) to evaluate the efficacy and safety of the IL-17 inhibitor ZL-1102 developed in-house by the company in treating chronic plaque psoriasis (CPP). The Phase 2 global clinical study of ZL-1102 is a randomized, double-blind, placebo-controlled, dose-range study for patients with mild to moderate CPP. In this 5-arm trial, approximately 250 patients will receive 16 weeks of topical treatment. According to Zaiding Pharmaceutical, as of the press date, ZL-1102 has not been approved domestically for the treatment of chronic plaque psoriasis.
再鼎医药：ZL-1102尚未在国内获批用于治疗慢性斑块状银屑病
Zaiding Pharmaceutical: ZL-1102 has not been approved in China to treat chronic plaque psoriasis
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.